Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2003
08/26/2003US6610730 Viricides; protease inbhibitor
08/26/2003US6610728 Method for treatment of non-rheumatoid arthritis
08/26/2003US6610727 Antitumor agents
08/26/2003US6610726 Compositions and agents for modulating cellular proliferation and angiogenesis
08/26/2003US6610725 Fluorinated imidazoline benzodioxane, preparation and therapeutic uses thereof
08/26/2003US6610724 3-Aminopyrazole inhibitors of cyclin dependent kinases
08/26/2003US6610723 Imidazole derivatives
08/26/2003US6610722 Inhibitors of prenyl-protein transferase
08/26/2003US6610720 Method for treating or preventing emesis
08/26/2003US6610719 Use of prostaglandin (PGE2) receptor a (EP4) selective agonists for the treatment of acute and chronic renal failure
08/26/2003US6610718 And dosage forms for treating rheumatoid arthritis
08/26/2003US6610716 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging
08/26/2003US6610715 Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same
08/26/2003US6610714 Non-nucleoside reverse transcriptase inhibitors
08/26/2003US6610713 Treating cell with cholinergic agonist
08/26/2003US6610711 4-phenylpiperidines for the treatment of pruritic dermatoses
08/26/2003US6610708 Cyclic amino compounds
08/26/2003US6610707 Heterocyclic compounds as inhibitors of rotomase enzymes
08/26/2003US6610706 Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
08/26/2003US6610704 Antithrombotic amides
08/26/2003US6610703 Administering long-chain N-alkyl derivative of deoxynojirimycin having from nine to about twenty carbon atoms in alkyl chain
08/26/2003US6610700 Inhibit binding of integrins to their ligands, use in immune or inflammatory disorders; 3-(4-((2,6-Naphthyridinyl)amino)-phenyl)-2-((2-(1-ethylpropyl)-3-oxo-1 -cyclopentenyl) amino)-propionic acid, for example
08/26/2003US6610699 Use of L-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
08/26/2003US6610698 Treatment of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and interleukin-8 mediated diseases
08/26/2003US6610697 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods
08/26/2003US6610696 Such as 2-(4-(2-(2-(4-(3,5-dimethyl-isoxazol-4-yl)-phenyl)-5-methyloxazol-4-yl) -ethyoxy)-phenoxy)-2-methylpropionic acid for treatment of diabetes (lowering serum triglycerides)
08/26/2003US6610695 Prophylaxis or treatment of CSBP/RK/p38 kinase mediated disease
08/26/2003US6610693 Fructosamine oxidase: antagonists and inhibitors
08/26/2003US6610692 Anticoagulants
08/26/2003US6610691 Carboxylic acid derivatives, their production and use
08/26/2003US6610690 Administering optically pure (S,S) enantiomer of reboxetine
08/26/2003US6610688 For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer
08/26/2003US6610687 Benzofuranylsulfonates
08/26/2003US6610686 Use of pirenoxine for the protection of corneal tissues in photokeractomy
08/26/2003US6610685 Fused indole derivatives
08/26/2003US6610684 Fused azepinone cyclin dependent kinase inhibitors
08/26/2003US6610683 Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
08/26/2003US6610682 Comprising insulin resistance improving agents in combination with drugs selected from angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors with a diluent or carrier
08/26/2003US6610681 Neurotherapeutic clavulanate composition and method
08/26/2003US6610678 Corticotropin-releasing factor antagonists; treating endocrine, psychiatric or neurologic disorders
08/26/2003US6610676 Nitrate esters of corticoid compounds and pharmaceutical applications thereof
08/26/2003US6610674 Method of treating inflammatory conditions with progesterone analogs
08/26/2003US6610673 Solid dose forms containing bismuth
08/26/2003US6610670 Cyclodextrin-drospirenone inclusion complexes
08/26/2003US6610667 Compositions for treatment of disorders of the oesophagus
08/26/2003US6610666 Hyaluronan product and process for manufacturing thereof
08/26/2003US6610665 2-(purin-9-yl)-tetrahydrofuran-3, 4-diol derivatives
08/26/2003US6610661 Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
08/26/2003US6610660 O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato) pyrrolidin-1-yl] diazen-1-ium-1,2-diolates
08/26/2003US6610652 Administration of at least one agent at a level which enhances NO and which does not appreciably alter normal systemic vascular tone
08/26/2003US6610651 Molecules that home to various selected organs or tissues
08/26/2003US6610650 Modulation of cellular transcription factor activity
08/26/2003US6610624 Method for enhancing catalytic activity with supercritical fluids
08/26/2003US6610541 Recombinant, active caspases and uses thereof
08/26/2003US6610539 Modulate the expression of the ribonucleotide reductase or the secA genes in microorganisms. This invention is also related to methods of using such oligonucleotides in inhibiting the growth of microorganisms. These antisense oligonucleotides are
08/26/2003US6610534 Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases
08/26/2003US6610523 Human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating
08/26/2003US6610484 Identifying material from a breast duct
08/26/2003US6610480 Identification of genes which are differentially expressed in hypertrophic cardiac tissue as compared to normal cardiac tissue. Accordingly, the present invention provides nucleotide sequences of genes and promotion or inhibition of the function
08/26/2003US6610477 Human DNA mismatch repair proteins
08/26/2003US6610329 Compositions for the delivery of antigens
08/26/2003US6610328 Amoxicillin-clarithromycin antibiotic composition
08/26/2003US6610327 Oral administration which comprises moxifloxacin, its salt and/or hydrate and lactose, to a process for its preparation, and to the use of this preparation for controlling bacterial infections in humans and animals.
08/26/2003US6610326 Divalproex sodium tablets
08/26/2003US6610325 Pharmaceutical medicine comprises an iron salt, not less than two polyols, a binding agent, a lubricating agent, and a flavoring agent. The dose of elemental iron is not less than 5 mg, and preferably 10 mg to 15 mg per tablet. The polyols are
08/26/2003US6610324 Analgesics; rheumatic diseases; muscular disorders; sleep disorders
08/26/2003US6610323 An enteric coated pharmaceutical dosage form comprising an H+,K+- ATPase inhibitor is disclosed. The dosage form comprises at least two portions of the H+,K+- ATPase inhibitor to be released in at least two consecutive pulses.
08/26/2003US6610322 Liposome suspension forms spontaneously upon adding a diacylglycerol-PEG lipid to an aqueous solution when the lipid has appropriate packing parameters and the adding occurs above the melting temperature of the lipid. Combinations of lipids
08/26/2003US6610321 Emulsion formulations for hydrophilic active agents
08/26/2003US6610320 Mixture of cocoa plant extract and antichloesterol agent
08/26/2003US6610319 Immune response modifier compounds for treatment of TH2 mediated and related diseases
08/26/2003US6610318 Sterile ophthalmological gel preparation applicable in drops and process for producing it
08/26/2003US6610315 Mixture of alcohol and water; presurgery scrub
08/26/2003US6610314 Comprising one or more proton donating agents and an alkyl phosphate anionic surfactant: high activity against numerous bacteria and other microorganisms
08/26/2003US6610307 Immunity against pasteurella haemolytica leukotoxin
08/26/2003US6610297 Compositions for treating allergies that include either BSW17 mimotope peptides or antibodies raised against BSW17 mimotope peptides. Also disclosed are methods for the treatment of allergies which involve administration of BSW17 mimeotope
08/26/2003US6610284 Preparation for prevention and healing of inflammation affections
08/26/2003US6610283 Poly(diallylamine)-based bile acid sequestrants
08/26/2003US6610274 Anti-inflammatory composition comprising tetracycline
08/26/2003US6610273 Container is provided with a non-metal interior surface so as to reduce chemical degradation
08/26/2003US6610272 Medicinal aerosol formulation comprising pioglitazone hydrochloride and a protective colloid amino acid stabilizer
08/26/2003US6610271 System and method for intranasal administration of lorazepam
08/26/2003US6610206 Buffered compositions for dialysis
08/26/2003CA2150892C A ruminant feed composition and a method for improving feed efficiency
08/26/2003CA2092211C Imidazole compounds, their preparation and use
08/25/2003CA2419773A1 Matrix metalloproteinase and tumor necrosis factor inhibitors
08/25/2003CA2405347A1 Medicament comprising nk4 gene or recombinant nk4 protein
08/24/2003WO2003059144A2 Method and process for producing youthful-appearing, small-pored, and smooth skin
08/24/2003CA2472450A1 Method and process for producing youthful-appearing, small-pored, and smooth skin
08/23/2003CA2473075A1 Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives
08/22/2003CA2418930A1 Use of agents that modulate pde11a activity
08/21/2003WO2003069327A1 Ion-sensitive field effect transistor and a method for producing a transistor of this type
08/21/2003WO2003069303A2 Antimalarial and antiproliferative pharmacophore models, novel tryptanthrin compounds having increased solubility, and methods of making and using thereof
08/21/2003WO2003069302A2 Alpha-substituted arylalkyl phosphonate derivatives
08/21/2003WO2003068955A2 Streptomyces avermitilis gene directing the ratio of b2:b1 avermectins
08/21/2003WO2003068946A1 Phenalenone derivatives, method for the production thereof and use of the same
08/21/2003WO2003068939A2 Cks1 INHIBITORS
08/21/2003WO2003068936A2 Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds
08/21/2003WO2003068931A2 Purification of the leading front migratory cells
08/21/2003WO2003068929A2 Methods of inhibiting hiv-1 vpr activity and hiv-1 infectivity using atr or rad17 inhibitors
1 ... 5365 5366 5367 5368 5369 5370 5371 5372 5373 5374 5375 5376 5377 5378 5379 5380 5381 5382 5383 5384 5385 ... 7860